Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 8/20 | 0.41 |
| ▸ | MAOA | P21397 | 7/20 | 0.41 |
| ▸ | KDM1A | O60341 | 6/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17104487 | 0.88 | RIPK1 (0.43) | KDM4EMAPTHPGDKDM1ASLC6A2 | |
| SCHEMBL4114277 | 0.84 | RIPK1 (0.41) | KDM4EMAPTHPGDKDM1ASLC6A2 | |
| SCHEMBL3991385 | 0.84 | RIPK1 (0.41) | KDM4EMAPTHPGDKDM1ASLC6A2 | |
| SCHEMBL4099326 | 0.84 | RIPK1 (0.41) | KDM4EMAPTHPGDKDM1ASLC6A2 | |
| SCHEMBL5805602 | 0.80 | KDM1A (0.39) | KDM1ASLC6A2SLC6A3RIPK1SLC6A4 | |
| SCHEMBL18226601 | 0.75 | KDM1A (0.40) | KDM4EMAOBMAOAKDM1ASLC6A2 | |
| SCHEMBL2538318 | 0.73 | — | — | |
| SCHEMBL2242113 | 0.72 | RIPK1 (0.48) | KDM1ASLC6A2SLC6A3RIPK1SLC6A4 | |
| SCHEMBL2428503 | 0.71 | POLB (0.32) | — | |
| SCHEMBL3993930 | 0.71 | ALDH1A1 (0.37) | KDM1ASLC6A3DRD3SLC6A4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3317279-B1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA-ROCHE INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-8324226-B2 | Therapeutic oxy-phenyl-aryl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| EP-2227460-B1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| EP-2227460-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009053694-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CHEK2, CHEK1, PLK1 | KDM4E 1238/4885MAPT 299/4885HPGD 2258/4885 |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | KDM4E 3174/4885MAPT 3426/4885HPGD 3197/4885 |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | KDM4E 3174/4885MAPT 3426/4885HPGD 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.